Long-term use of proton pump inhibitors (PPIs) is common in patients with muscle
wasting-related chronic diseases. We explored the hypothesis that the use of PPIs may contribute to
a reduction in muscle mass and function in these patients. Literature indicates that a PPI-induced
reduction in acidity of the gastrointestinal tract can decrease the absorption of, amongst others,
magnesium. Low levels of magnesium are associated with impaired muscle function. This
unwanted side-effect of PPIs on muscle function has been described in different disease backgrounds.
Furthermore, magnesium is necessary for activation of vitamin D. Low vitamin D and magnesium
levels together can lead to increased inflammation involved in muscle wasting. In addition, PPI use
has been described to alter the microbiota’s composition in the gut, which might lead to increased
inflammation. However, PPIs are often provided together with nonsteroidal anti-inflammatory drugs
(NSAIDs), which are anti-inflammatory. In the presence of obesity, additional mechanisms could
further contribute to muscle alterations. In conclusion, use of PPIs has been reported to contribute to
muscle function loss. Whether this will add to the risk factor for development of muscle function loss
in patients with chronic disease needs further investigation.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:89035 |
| Date | 16 January 2024 |
| Creators | Vinke, Paulien, Wesselink, Evertine, van Orten-Luiten, Wout, van Norren, Klaske |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 323 |
Page generated in 0.0018 seconds